J Korean Rheum Assoc.
2006 Dec;13(4):306-310.
Successful Treatment with Etanercept in a Patient with Adult-onset Still's Disease
- Affiliations
-
- 1Department of Rheumatology, Chonnam National University Medical School, Gwangju, Korea. ppaarrkkyw@empal.com
Abstract
- Adult-onset Still's disease (AOSD) is a rare systemic inflammatory disorder of unknown etiology. Non-steroidal anti-inflammatory drugs (NSAIDs), steroids, disease modifying anti-rheumatic drugs (DMARDs), immunosuppressives and intravenous immunoglobulin (IVIG) have been used to control the disease. It was suggested that several pro-inflammatory cytokines, such as interleukin (IL)-6, IL-8, IL-18, and tumor necrosis factor (TNF)-alpha, play an important role in its pathogenesis. Recent reports showed the clinical effectiveness of TNF-alpha blockers (infliximab and etanercept) in refractory AOSD. We report a case successfully treated with etanercept in the early AOSD refractory to the combination therapy of high-dose prednisolone and cyclosporine (CSA).
MeSH Terms
-
Antirheumatic Agents
Cyclosporine
Cytokines
Etanercept
Humans
Immunoglobulins
Interleukin-18
Interleukin-8
Interleukins
Prednisolone
Steroids
Still's Disease, Adult-Onset*
Tumor Necrosis Factor-alpha
Antirheumatic Agents
Cyclosporine
Cytokines
Immunoglobulins
Interleukin-18
Interleukin-8
Interleukins
Prednisolone
Steroids
Tumor Necrosis Factor-alpha
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Real-World Experience with Etanercept Therapy and the Switching Pattern among Korean Patients with Psoriasis after Withdrawal of Etanercept
- A Case of Adult Onset Still's Disease
- Long Term Safety and Efficacy of Etanercept in Juvenile Idiopathic Arthritis in a Single Center
- Recurrent Pneumothorax after Etanercept Therapy in a Rheumatoid Arthritis Patient: A Case Report
- Two Cases of Refractory Adult-Onset Still's Disease Responding to Anakinra
